 Windtree Therapeutics Inc NASDAQ: WINT shares are trading higher Wednesday after the company announced topline results from the Phase 2 SEISMiC study of istaroxime in early cardiogenic shock. Istaroxime is a dual mechanism therapy designed to improve both systolic and diastolic cardiac. 